Literature DB >> 33831245

Pancreas cancer: Therapeutic trials in metastatic disease.

James W Smithy1, Eileen M O'Reilly1.   

Abstract

Metastatic pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-related mortality in 2021. Cytotoxic therapies are the therapeutic mainstay for PDAC. The recent approval of olaparib as maintenance therapy for germline BRCA1/2-mutated PDAC and pembrolizumab for mismatch repair deficient PDAC represent molecularly targeted approaches for this disease. Investigational therapeutic strategies include targeting the stroma, metabolism, tumor microenvironment, and the immune system, and selected approaches are reviewed herein.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  KRAS; clinical trials; genetics; metastatic disease; pancreatic cancer

Mesh：

Year:  2021        PMID： 33831245      PMCID： PMC8606164          DOI： 10.1002/jso.26359

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  81 in total

Review 1.  Pancreatic cancer.

Authors:  Jonathan D Mizrahi; Rishi Surana; Juan W Valle; Rachna T Shroff
Journal:  Lancet       Date:  2020-06-27       Impact factor: 79.321

Review 2.  Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis.

Authors:  A Creemers; S Krausz; M Strijker; M J van der Wel; E C Soer; R J Reinten; M G Besselink; J W Wilmink; M J van de Vijver; C J M van Noesel; J Verheij; S L Meijer; F Dijk; M F Bijlsma; M G H van Oijen; H W M van Laarhoven
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-08-08       Impact factor: 10.680

3.  Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity.

Authors:  Ritsuko Sawada; Shu-Man Sun; Xiaohong Wu; Feng Hong; Govind Ragupathi; Philip O Livingston; Wolfgang W Scholz
Journal:  Clin Cancer Res       Date:  2011-02-22       Impact factor: 12.531

4.  BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.

Authors:  Bruno Bockorny; Valerya Semenisty; Teresa Macarulla; Erkut Borazanci; Brian M Wolpin; Salomon M Stemmer; Talia Golan; Ravit Geva; Mitesh J Borad; Katrina S Pedersen; Joon Oh Park; Robert A Ramirez; David G Abad; Jaime Feliu; Andres Muñoz; Mariano Ponz-Sarvise; Amnon Peled; Tzipora M Lustig; Osnat Bohana-Kashtan; Stephen M Shaw; Ella Sorani; Marya Chaney; Shaul Kadosh; Abi Vainstein Haras; Daniel D Von Hoff; Manuel Hidalgo
Journal:  Nat Med       Date:  2020-05-25       Impact factor: 53.440

5.  Metastatic Pancreatic Cancer: ASCO Guideline Update.

Authors:  Davendra P S Sohal; Erin B Kennedy; Pelin Cinar; Thierry Conroy; Mehmet S Copur; Christopher H Crane; Ignacio Garrido-Laguna; Michelle W Lau; Tyler Johnson; Smitha Krishnamurthi; Cassadie Moravek; Eileen M O'Reilly; Philip A Philip; Shubham Pant; Manish A Shah; Vaibhav Sahai; Hope E Uronis; Neeha Zaidi; Daniel Laheru
Journal:  J Clin Oncol       Date:  2020-08-05       Impact factor: 50.717

6.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Authors:  Talia Golan; Pascal Hammel; Michele Reni; Eric Van Cutsem; Teresa Macarulla; Michael J Hall; Joon-Oh Park; Daniel Hochhauser; Dirk Arnold; Do-Youn Oh; Anke Reinacher-Schick; Giampaolo Tortora; Hana Algül; Eileen M O'Reilly; David McGuinness; Karen Y Cui; Katia Schlienger; Gershon Y Locker; Hedy L Kindler
Journal:  N Engl J Med       Date:  2019-06-02       Impact factor: 91.245

7.  Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.

Authors:  Kirsten L Bryant; Clint A Stalnecker; Daniel Zeitouni; Jennifer E Klomp; Sen Peng; Andrey P Tikunov; Venugopal Gunda; Mariaelena Pierobon; Andrew M Waters; Samuel D George; Garima Tomar; Björn Papke; G Aaron Hobbs; Liang Yan; Tikvah K Hayes; J Nathaniel Diehl; Gennifer D Goode; Nina V Chaika; Yingxue Wang; Guo-Fang Zhang; Agnieszka K Witkiewicz; Erik S Knudsen; Emanuel F Petricoin; Pankaj K Singh; Jeffrey M Macdonald; Nhan L Tran; Costas A Lyssiotis; Haoqiang Ying; Alec C Kimmelman; Adrienne D Cox; Channing J Der
Journal:  Nat Med       Date:  2019-03-04       Impact factor: 53.440

8.  Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

Authors:  Eileen M O'Reilly; Do-Youn Oh; Neesha Dhani; Daniel J Renouf; Myung Ah Lee; Weijing Sun; George Fisher; Aram Hezel; Shao-Chun Chang; Gordana Vlahovic; Osamu Takahashi; Yin Yang; David Fitts; Philip Agop Philip
Journal:  JAMA Oncol       Date:  2019-10-01       Impact factor: 31.777

9.  Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma.

Authors:  Kenneth H Yu; Mark Ricigliano; Brian McCarthy; Joanne F Chou; Marinela Capanu; Brandon Cooper; Andrew Bartlett; Christina Covington; Maeve A Lowery; Eileen M O'Reilly
Journal:  Cancers (Basel)       Date:  2018-11-24       Impact factor: 6.639

10.  Mutation-Derived Neoantigens for Cancer Immunotherapy.

Authors:  John C Castle; Mohamed Uduman; Simarjot Pabla; Robert B Stein; Jennifer S Buell
Journal:  Front Immunol       Date:  2019-08-07       Impact factor: 7.561
View more
  2 in total

1.  Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.

Authors:  Felix Orben; Katharina Lankes; Christian Schneeweis; Zonera Hassan; Hannah Jakubowsky; Lukas Krauß; Fabio Boniolo; Carolin Schneider; Arlett Schäfer; Janine Murr; Christoph Schlag; Bo Kong; Rupert Öllinger; Chengdong Wang; Georg Beyer; Ujjwal M Mahajan; Yonggan Xue; Julia Mayerle; Roland M Schmid; Bernhard Kuster; Roland Rad; Christian J Braun; Matthias Wirth; Maximilian Reichert; Dieter Saur; Günter Schneider
Journal:  JCI Insight       Date:  2022-05-23

2.  [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma.

Authors:  Felix N Harder; Friederike Jungmann; Georgios A Kaissis; Fabian K Lohöfer; Sebastian Ziegelmayer; Daniel Havel; Michael Quante; Maximillian Reichert; Roland M Schmid; Ihsan Ekin Demir; Helmut Friess; Moritz Wildgruber; Jens Siveke; Alexander Muckenhuber; Katja Steiger; Wilko Weichert; Isabel Rauscher; Matthias Eiber; Marcus R Makowski; Rickmer F Braren
Journal:  EJNMMI Res       Date:  2021-07-28       Impact factor: 3.138
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.